Beaming

Combination method of traditional emulsion PCR with magnetic particles and flow cytometry.

In oncology, predictive biomarkers are of great importance for the effectiveness and individual response of treatment. They can be used to assess whether a particular treatment is likely to be effective in an individual patient. RAS mutation analyses enable targeted therapy.

The BEAMing test procedure is a simplified method for the blood-based determination of the RAS mutation status of tumors. It is therefore an alternative to tissue biopsies or surgical interventions and can also be used if no tumour tissue is present or if a rapid test result is an absolute prerequisite for the therapy strategy.

The test determines an extensive panel of 34 KRAS and NRAS mutations. Its use in routine diagnostics is in prospect: the declaration of conformity according to the European harmonization directives (CE marking) is expected in the coming months.

OncoBEAM© test

1. Bardelli A et al (2017) Liquid biopsies, what we do not know (yet). Cancer cell 31: 172-179